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Abstract
Introduction: Rheumatoid arthritis (RA) is associated with an increased risk for cardiovascular disease (CVD), and it
has been postulated that RA disease-related inflammation contributes to endothelial dysfunction. The aim of the
present work was to examine predictors (RA-related and CVD risk factors) and anti-tumor necrosis factor-alpha
(anti-TNF-a) treatment effects on endothelial function in different vascular beds.
Methods: Microvascular endothelial function (laser Doppler imaging with iontophoresis of acetylcholine and
sodium-nitroprusside), and macrovascular endothelial function (flow-mediated dilatation and glyceryl-trinitrate-
mediated dilatation) were analyzed in parallel with disease activity. Individual CVD risk factors and global CVD risk
were assessed cross-sectionally in 99 unselected RA patients and longitudinally (baseline, 2 weeks, and 3 months)
in 23 RA patients commencing anti-TNF-a therapy.
Results: In this cross-sectional study, regression analyses revealed that markers of RA disease-related inflammation
were not associated with microvascular or macrovascular endothelium-dependent function (P > 0.05); global CVD
risk inversely correlated with microvascular endothelium-dependent function (P < 0.01) and with macrovascular
endothelium-independent function (P < 0.01). In the longitudinal study, only microvascular endothelium-
dependent function showed an improvement after 2 weeks of anti-TNF-a treatment when compared with baseline
(437% ± 247% versus 319% ± 217%; P = 0.001), but no association was evident between change in endothelial
function and change in inflammatory markers.
Conclusions: Classical CVD risk may influence endothelial function more than disease-related markers of
inflammation in RA. Classical CVD risk factors and anti-TNF-a medication have different effects on microvascular
and macrovascular endothelial function, suggesting that combined CVD-prevention approaches may be necessary.
Prospective studies examining whether assessments of vascular function are predictive of long-term CV outcomes
in RA are required.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
musculoskeletal disease that affects ~0.8% of the adult
population. RA also associates with an increased risk for
cardiovascular disease (CVD) [1], which is only partially
explained by traditional CVD risk factors [2]. The
inflammatory processes of RA and CVD are remarkably
similar, suggesting that RA disease-related inflammation
might contribute to the excess CVD risk [3].
The vascular endothelium is responsible for maintain-
ing an atheroprotective environment through the release
of vasoactive factors, particularly nitric oxide (NO). Non-
invasive assessments of peripheral endothelial function in
the microcirculation and the macrocirculation may pre-
dict adverse cardiovascular outcomes in patients at risk
of developing, or with prevalent CVD [4]. Endothelial
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cells differ in structure and phenotype depending on ves-
sel type [5], and heterogeneous responses to in vitro sti-
mulation are displayed in different vascular beds [6],
suggesting that endothelial dysfunction (ED) may occur
differentially in different vascular beds [6]. Evidence sug-
gests that coronary microvascular disease is apparent in
the absence of macrovascular disease in RA [7], and we
previously showed that microvascular and macrovascular
endothelial function are independent of each other in
this population [8]. These findings highlight the impor-
tance of assessing endothelial function in different vascu-
lar beds.
A number of studies have reported the presence of
microvascular and macrovascular ED in RA patients rela-
tive to age- and sex-matched healthy controls, which can
be improved after treatment with antiinflammatory medi-
cations (such as anti-tumor necrosis factor-alpha (anti-
TNF-a) [9]. Even though an association between
endothelial function and inflammation is often assumed,
surprisingly few studies have actually examined this [9].
Cross-sectional studies report equivocal findings; some
find an association between inflammatory markers and
endothelial function [10], whereas others do not [11].
Longitudinal studies revealed no correlation between
changes in inflammatory markers and changes in
endothelial function [12,13], and the improvement in
microvascular endothelial function after treatment
occurred without any change in inflammatory markers
[14]. Thus, it remains possible that endothelial function
in RA is determined by factors other than systemic
inflammation, such as CVD risk factors [9].
The prevalence of classical CVD risk factors is
increased in patients with RA [2], and their control is
worse [15], compared with that of the general population
[16]. At present, no studies have examined associations
between classical CVD risk factors in the microcircula-
tion, and only a very few studies have been conducted in
the macrocirculation, with inconsistent findings [9]. CVD
risk can be calculated by incorporating individual CVD
risk factors into algorithms to yield “global” CVD risk
scores. Examples of such algorithms are the Framingham
Risk Score (FRS) [17] and the Systematic Coronary Risk
Evaluation (SCORE) [18]. However, these algorithms do
not account for systemic inflammation, whereas the
more recent Reynolds risk score does, as it includes
C-reactive protein (CRP) in the algorithm. In addition,
QRISK2 is the only CVD-risk algorithm that incorporates
the presence of RA, as well as socioeconomic status and
ethnicity [19]. To our knowledge, the relation between
these risk algorithms and microvascular and macrovascu-
lar endothelial function has not been investigated in RA.
The objectives of the present studies were to examine
determinants of microvascular and macrovascular
endothelial function in RA, with a specific focus on disease-
related markers of inflammation and classical CVD risk.
Materials and methods
Cross-sectional study
Ninety-nine consecutive rheumatoid arthritis (RA)
patients were recruited from the rheumatology outpatient
clinics of the Dudley Group of Hospitals NHS Trust,
United Kingdom. All patients met the retrospective appli-
cation of the 1987 revised RA criteria of the American
College of Rheumatology [20]. Patients were excluded if
they had previously confirmed acute coronary syndrome
or established cardiovascular disease (CVD).
Longitudinal study
Twenty-three RA patients from study one, who were
about to start anti-TNF-a therapy on clinical indication
(UK guidelines), were recruited into a 3-month prospec-
tive study. The patients had not previously received any
other biologic drugs, including anti-TNF-a. Patients were
assessed before starting anti-TNF-a (pre-treatment), and
2 weeks and 3 months after initiation of treatment.
Fifteen (65%) of the anti-TNF-a patients were started on
40 mg of adalimumab, six (26%) on 50 mg of etanercept,
and two (9%) on infliximab with a dosage of 3 mg/kg.
Patients continued treatment with other drugs during the
study period, and these included 16 (70%) patients taking
methotrexate, one (4%) taking cyclooxygenase II inhibi-
tors, six (26%) taking nonsteroidal antiinflammatory
drugs, six (26%) taking prednisolone, four (18%) taking
anti-hypercholesterolemic drugs, and five (22) taking
antihypertensive drugs. No change in any of these medi-
cations or their doses occurred during the follow-up per-
iod. Assessments at 2 weeks and 3 months were
performed before receiving the next dose of the anti-
TNF-a drug.
The study had ethics committee approval, and all par-
ticipants provided written informed consent.
Study protocol
Patients reported to a thermoregulated (22°C ± 0.9°C) vas-
cular laboratory after a 12-hour overnight fast. They were
asked to refrain from exercise 24 hours before the session,
and from smoking, 12 hours before the session. For ethical
reasons, drug regimens were not interrupted. All partici-
pants underwent a detailed clinical examination, and
demographic information was collected with a question-
naire. The disease activity score (DAS28) [21] and the
Stanford Health Assessment Questionnaire (HAQ) [22]
were completed, along with the patients global CVD risk
scores. Blood pressure measurements were taken by using
an automated blood pressure monitor (Datascope Accu-
tor, Mahwah, NJ, USA). A blood sample was also obtained.
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Patients in the cross-sectional study were assessed at one
time point only, whereas patients in the longitudinal study
were assessed at pre-treatment baseline, and at 2 weeks
and 3 months after treatment with anti-TNF-a.
Blood sampling
The serum was analyzed for total cholesterol, high-den-
sity lipoprotein cholesterol (HDL), triglycerides, CRP,
and glucose by using a Vitros 5.1 FS Chemistry system.
Westergren erythrocyte sedimentation rate (ESR) was
measured by using the Starrsed Compact (Mechatronics
BV, Hoorn, The Netherlands). Insulin was estimated
from serum stored at -20°C by using an Immulite 2500
analyzer (Diagnostic Products Corporation, California,
USA). Insulin sensitivity was assessed by calculating the
Homeostasis Model Assessment Insulin Resistance
(HOMA IR) and Quantitative Insulin Sensitivity Check
Index (QUICKI), as previously described [23,24]. All tests
were carried out in the routine and research laboratories
of Dudley Group NHS Foundation Trust.
Global CVD risk
Four separate global CVD-risk algorithms were used:
FRS [25], SCORE [18], Reynolds risk score [26], and the
QRISK2 [19]. These algorithms were calculated at base-
line for patients in the cross-sectional and longitudinal
studies.
Microvascular endothelial function
Endothelial function of the microvasculature was assessed
non-invasively by using LDI (Moor LDI 2 SIM; Moor
Instruments Ltd, Devon, UK) with iontophoresis of 1%
acetylcholine (ACh, endothelium-dependent) and 1%
sodium-nitroprusside (SNP, endothelium-independent)
(Sigma Chemical Co, Montvale, NJ, USA) in 2.5 ml solu-
tion containing 0.5% saline, by a single observer (AS). The
technique was performed according to previously estab-
lished guidelines [27] and has been described in detail pre-
viously [28]. This technique has an intraobserver
coefficient of variation (CV) for ACh and SNP of 6.5% and
5.9%, respectively, for AS.
Macrovascular endothelial function
Assessment of macrovascular endothelium-dependent
function was performed by using flow-mediated dilatation
(FMD) with high-resolution ultrasonography of the bra-
chial artery (Acuson Antares ultrasound system; Siemens
PLC, Camberley, UK) according to previously established
guidelines [29]. Endothelium-independent responses were
examined by administration of a 500-μg sublingual gly-
ceryl-trinitrate (GTN) tablet (Alpharma, Barnstaple, UK).
The intraobserver CV for the study ultrasonographer (AS)
was 10.7% for FMD and 11.8% for GTN assessments,
respectively. For all vascular tests, endothelial function was
expressed as the percentage increase in perfusion or dia-
meter from baseline, and all analysis was carried out off-
line by AS, who was blinded to the identity of the patient.
Statistical analysis
Statistical analysis was performed by using SPSS15 (SPSS
Inc., Chicago, IL, USA). Variables were tested for normal-
ity by the Kolmogorov-Smirnov test. Means and standard
deviations (SD) were calculated for normally distributed
continuous variables, and proportions for categorical
variables. Non-normally distributed data were presented
as median (25th to 75th percentile values). Log transfor-
mation was performed for positively skewed variables, as
appropriate. Variations in degrees of freedom reflect
occasionally missing data.
Cross-sectional study
To assess determinants of vascular function, univariate
linear regression (continuous variables) and logistic
regression (dichotomous variables) was used. Inflamma-
tory markers, global CVD risk, and CVD risk factors
were entered as independent variables, with each mea-
sure of vascular function entered separately as the depen-
dent variable. Step-wise multiple regression analysis was
conducted to determine independent predictors of
endothelial function, and only those variables that came
out as significantly associated with endothelial function
in the univariate analyses were entered into this analysis.
The entry probability was 0.05, and none of the variables
were forced back into the model.
Longitudinal study
Changes (Δ) in each parameter of endothelial function,
CVD risk factors, and disease-related markers of sys-
temic inflammation were assessed by using three Time
(pre-treatment baseline, 2 weeks, and 12 weeks)
repeated-measures analysis of variance (ANOVA).
Where appropriate, Fisher LSD post hoc tests were used
for pair-wise comparisons. Endothelial function did not
differ between the three different types of anti-TNF-a
treatment at any time point (data not shown); therefore,
all treatments were analyzed together. The Δ in
endothelial function and disease-related parameters was
calculated by subtracting the pretreatment baseline
values from the values obtained at 2 and 12 weeks,
respectively. Linear regression was used to examine
whether changes in endothelial function were related to





The general and disease-related characteristics for
patients in the cross-sectional study are presented in
Table 1. Individual CVD risk factors as well as the
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Disease-related markers of inflammation
No association was apparent between microvascular
endothelium-dependent or endothelium-independent
function and any of the inflammatory parameters (ESR,
CRP, DAS28, or disease duration) (Table 3).
Individual classical CVD risk factors
Both microvascular endothelium-dependent and
endothelium-independent function were inversely corre-
lated with age only (see Tables 3 and 4).
Global CVD risk
The FRS, SCORE, Reynolds risk score, and QRISK2 were
all inversely associated with microvascular endothelium-
dependent function (Table 4), but no associations were evi-




Disease-related markers of inflammation
None of the inflammatory parameters (ESR, CRP, DAS28,
or disease duration) was associated with macrovascular
endothelium-dependent or endothelium-independent
function (Table 3).
Individual classical CVD risk factors
Age was the only individual CVD risk factor associated
with both macrovascular endothelium-dependent and
endothelium-independent function (see Tables 3 and 4).
In addition, resting SBP, insulin, HOMA, and QUICKI
were associated with macrovascular endothelium-inde-
pendent function. A modest association was noted
between hypercholesterolemia, hypertension, and macro-
vascular endothelium-independent function (Tables 3
and 4). Step-wise multiple regression analysis revealed
that QUICKI (b = 0.28; R2 = 0.052; P < 0.01) and SBP (b
= -0.13; R2 = 0.052; P < 0.05) were independently
Table 1 General and disease characteristics as well as




Sex female n (%) 72 (73) 99
Disease characteristics
RF positive n (%) 70 (78) 90
Disease duration (years) 11 ± 10 74
ESR (mm/hr) 17.0 (8.8-28.3) 90
CRP (mg/L) 5.0 (2.9-13.50) 93
DAS28 3.6 ± 1.3 93
HAQ 1.7 ± .87 95
RA medications
Methotrexate n (%) 60 (60) 99
Prednisolone n (%) 22 (22) 99
NSAIDS n (%) 18 (18) 99
Cyclooxygenase II inhibitors n (%) 11 (11) 99
Anti-TNF-a therapy n (%) 11 (11) 99
CVD medications
Antihypertensive n (%) 25 (25) 99
Antihypercholesterolemic n (%) 12 (12) 99
Beta-blocker n (%) 7 (7) 99
Calcium channel blocker n (%) 5 (5) 99
Microvascular function
Endothelium-dependent (ACh%) 236 (152-407) 94
Endothelium-independent (SNP%) 261 (181-384) 94
Macrovascular function
Endothelium-dependent (FMD%) 9.5 (4.8-13.5) 96
Endothelium-independent (GTN%) 24.0 (16.3-30.4) 93
Results are expressed as number (percentage), mean ± SD, or median (25th to
75th) percentile, as appropriate. Ach, acetylcholine; CRP, C-reactive protein;
CVD, cardiovascular disease; DAS28, disease activity score in 28 joints; ESR,
erythrocyte sedimentation rate; FMD, flow-mediated dilatation; GTN, glyceryl
trinitrate; HAQ, Health Assessment Questionnaire, NSAID, nonsteroidal
antiinflammatory drug; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF,
tumor necrosis factor; SNP, sodium nitroprusside.
Table 2 Individual CVD risk factors and global CVD risk
scores for patients in the cross-sectional study
RA patients Number
Individual CVD risk factors
Age (years) 56 ± 12 99
BMI (kg/m2) 30 ± 6 99
SBP (mm Hg) 133 ± 16 96
DBP (mm Hg) 81 ± 10 96
Total cholesterol (mM) 5.1 ± 1.0 93
HDL-C (mM) 1.5 ± 0.3 93
Triglycerides (m) 1.5 ± 0.7 93
TC/HDL ratio 3.5 ± 8.5 93
Glucose (mM) 4.6 (4.3-4.9) 91
Insulin (pM) 70.4 (40.6-105.5) 89
HOMA IR 2.1 (1.1-3.2) 87
QUICKI 0.35 ± 0.41 87
Cigarette-smoking status
Never smoked 38 (42) 91
Previous smokers 36 (40) 91
Current smokers 17 (19) 91
Global CVD risk scores
Framingham Risk Score 5 (3-10) 87
TC SCORE 1 (0-2) 64
TC/HDL SCORE 1 (0-2) 64
Reynolds Risk Score 8 (3-14) 65
QRISK 2 15 (7-26) 95
Results are expressed as median (25th to 75th percentile values) or mean ± SD,
as appropriate. BMI, body mass index; DBP, diastolic blood pressure; HDL-C,
high-density lipoprotein cholesterol; HOMA IR, homeostasis model assessment
insulin resistance; QUICKI, quantitative insulin sensitivity check index; SBP,
systolic blood pressure; SCORE, systematic coronary risk evaluation; TC, total
cholesterol.
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associated with macrovascular endothelium-independent
function.
Global CVD risk
Macrovascular endothelium-dependent function was
inversely associated with Reynolds risk score and
QRISK2, whereas macrovascular endothelium-indepen-
dent function was associated with FRS, Reynolds risk
score, and QRISK2 (Table 4).
Longitudinal study
Patient characteristics
Patients in the longitudinal study, had an age (mean ±
standard deviation) of 54 ± 15 years; 15 (65%) were
female patients; 20 (87%) were rheumatoid factor posi-
tive; and the disease duration was 11 ± 11 years.
Eleven (48.8%) patients were never smokers; seven
(30%), previous smokers; and five (22%) were current
smokers.
Longitudinal effect of anti-TNF-a treatment on disease-
related inflammation
The repeated measures ANOVA revealed an overall
effect for morning stiffness, CRP, ESR, DAS28, and
HAQ (Table 5). Post hoc analyses revealed that morning
stiffness, CRP, DAS28, and HAQ were reduced after 2
weeks and remained low after 12 weeks of treatment.
ESR improved 2 weeks after commencing treatment, but
Table 3 Linear regression analysis for general and RA disease-related characteristics and endothelial function in RA
patients from the cross-sectional study











Disease duration b = -0.12, P = 0.29 b = 0.21, P = 0.07 b = -0.04 P = 0.76 b = -0.12, P = 0.34
LogCRP b = -0.61, P = 0.05 b = 0.10, P = 0.32 b = 0.15, P = 0.13 b = 0.00, P = 0.97
LogESR b = -0.09, P = 0.41 b = 0.18, P = 0.10 b = -0.01, P = 0.95 b = -0.08, P = 0.46
DAS28 b = 0.15, P = 0.15 b = 0.02, P = 0.84 b = 0.06, P = 0.59 b = -0.01, P = 0.93
General characteristics
Age b = -0.37, R2 = 0.135c b = -0.20, R2 = 0.042a b = -0.24, R2 = 0.55a b = -0.36, R2 = 0.126c
BMI b = 0.21, P = 0.05 b = 0.08, P = 0.41 b = -0.12, P = 0.26 b = -0.21, P = 0.05
Resting SBP b = -0.11, P = 0.30 b = -0.02, P = 0.88 b = -0.11, P = 0.27 b = -0.27, R2 = 0.066b
Resting DBP b = 0.04, P = 0.67 b = 0.08, P = 0.44 b = -0.12, P = 0.25 b = -0.05, P = 0.61
RA disease-related characteristics and general characteristics were entered as independent variables, whereas microvascular and macrovascular endothelial
functions were entered as dependent variables in the regression analysis. BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score in 28
joints; DBP, diastolic blood pressure; ESR, erythrocyte sedimentation rate; SBP, systolic blood pressure. aP < 0.05; bP < 0.01; cP < 0.001. R2 value is shown for all
significant associations only.
Table 4 Linear and binary regression between classical CVD risk and endothelial function in RA patients from the
cross-sectional study
Microvascular function Macrovascular function
Endothelium-dependent Endothelium- independent Endothelium- dependent Endothelium- independent
CVD risk factors
Insulin b = 0.13, P = 0.23 b = 0.04, P = 0.73 b = -0.04, P = 0.71 b = -0.25, R2 = 0.065a
HOMA b = 0.09, P = 0.41 b = -0.01, P = 0.95 b = -0.06, P = 0.61 b = -0.23, R2 = 0.052a
QUICKI b = -0.07, P = 0.53 b = -0.02, P = 0.88 b = 0.11, P = 0.30 b = 0.30, R2 = 0.095b
High cholesterol OR = 1.01 (0.99-1.00) OR = 1.00 (0.99-1.00) OR = 1.08 (0.99-1.17) OR = 1.09 (1.02-1.17)a
Hypertension OR = 1.00 (1.00-1.00) OR = 1.00 (0.99-1.00) OR = 1.08 (0.99-1.17) OR = 1.07 (1.01-1.14)a
Cigarette smoking OR = 1.00 (1.00-1.00) OR = 1.00 (1.00-1.00) OR = 1.04 (0.97-1.13) OR = 1.04 (0.99-1.10)
Global CVD risk
FRS b = -0.26, R2 = 0.068b b = -0.18, P = 0.09 b = -0.12, P = 0.26 b = -0.32, R2 = 0.101b
TC score b = -0.28, R2 = 0.077a b = -0.17, P = 0.18 b = -0.23, P = 0.08 b = -0.14, P = 0.30
TC/HDL score b = -0.26, R2 = 0.068a b = -0.17, P = 0.19 b = -0.25, P = 0.05 b = -0.17, P = 0.18
Reynolds Risk Score b = -0.30, R2 = 0.088a b = -0.12, P = 0.37 b = -0.27, R2 = 0.072a b = -0.51, R2 = 0.259b
QRISK 2 b = -0.33, R2 = 0.109b b = -0.19, P = 0.08 b = -0.22, R2 = 0.048a b = -0.51, R2 = 0.255b
CVD risk factors and global CVD risk scores were entered as independent variables, and endothelial functions, as dependent variables in the linear and binary
regression analysis. Odds ratio (OR) with 95% confidence interval is presented for all binary regression analysis. CVD, cardiovascular disease; FRS, Framingham risk
score; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; QUICKI, quantitative insulin sensitivity check index; SCORE, systematic coronary risk
evaluation; TC, total cholesterol. aP < 0.05; bP < 0.01. R2 value is shown for all significant associations only.
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was similar to baseline levels at 12 weeks. None of
the parameters differed significantly between weeks 2
and 12.
Longitudinal effect of anti-TNF-a treatment on classical
CVD risk
ANOVAs revealed an overall Time effect for HDL cho-
lesterol (F (2, 22) = 4.98; P < 0.01), SBP (F (2, 22) =
5.63, P < 0.01) and DBP (F (2, 22) = 6.99; P < 0.01).
Post hoc analysis showed that HDL cholesterol was
higher at 2 weeks, but returned to baseline levels by 12
weeks. No change was found in the TC/HDL ratio with
anti-TNF-a treatment. SBP and DBP were lower at 2
and 12 weeks relative to baseline. No change was noted
in any other parameters.
Longitudinal effect of anti-TNF-a treatment on
microvascular function
ANOVA revealed an overall Time effect for microvascu-
lar endothelium-dependent function after treatment
(Table 6). Post hoc analysis confirmed that microvascu-
lar endothelium-dependent function was increased at 2
weeks, but not different from baseline at 12 weeks. No
change in microvascular endothelium-independent func-
tion was found after treatment.
Longitudinal effect of anti-TNF-a treatment on
macrovascular function
Both macrovascular endothelium-dependent and
endothelium-independent function did not change in
response to anti-TNF-a treatment.
Association between changes in inflammation, CVD risk




Linear regression analysis revealed that changes in
inflammatory parameters and CVD risk factors were not
correlated with change in microvascular endothelium-
dependent or endothelium-independent function at 2




In the macrovasculature, ΔESR and ΔDAS28 were not
related to change in macrovascular endothelium-dependent
function at 2 and 12 weeks. However, ΔCRP was associated
with change in macrovascular endothelium-dependent
function at 2 weeks (b = 0.52; R2 = 0.269; P < 0.01), but not
at 12 weeks. No associations were seen between change in
CVD risk factors and macrovascular endothelium-depen-
dent and -independent function at any time point.
Baseline inflammation and changes in endothelial
function Baseline ESR associated with the change in
microvascular endothelium-dependent function at 2
weeks (b = 0.48; R2 = 0.198; P < 0.05) and baseline CRP
was associated with change in microvascular endothe-
lium-dependent function at 2 weeks (b = 0.47; R2 =
0.185; P < 0.05) and at 12 weeks (b = 0.42; R2 = 0.138;
P < 0.05). This suggests that those with high levels of
inflammation at baseline showed the greatest improve-
ment in microvascular endothelium-dependent function.
No other significant correlations emerged from these
analyses. The same analyses were repeated for the global
CVD risk algorithms, but no associations were apparent.
Discussion
These findings revealed that, in the cross-sectional
study, disease-related markers of systemic inflammation
Table 5 Disease-related characteristics at baseline, 2 weeks, and 12 weeks
Baseline 2 weeks 12 weeks Treatment effect
F (2, 22) =
Morning stiffness (min) 116 ± 75 72 ± 81a 55 ± 83a 4.33, P = 0.02
CRP (mg/L) 10 (4-14) 3 (2.9-6)a 5 (2.9-10)a 12.89, P < 0.001
ESR (mm/hr) 16 (9-34) 10 (5-21)a 17 (5-27) 4.98, P = 0.01
DAS28 4.17 ± 0.96 2.74 ± 1.4a 2.64 ± 1.07a 15.92, P < 0.001
HAQ 2.1 ± 0.5 1.3 ± 0.9a 1.3 ± 0.9a 17.18, P < 0.001
Results are expressed as median (25th to 75th percentile values) or mean ± standard deviation, as appropriate. aDifferent from baseline. CRP, C-reactive protein;
DAS28, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire.
Table 6 Endothelial function during treatment in the longitudinal study
Baseline 2 weeks 12 weeks Treatment effect Degrees of freedom
Microvascular function
Endothelium-dependent (Ach%) 314 ± 214 423 ± 250a 348 ± 209b F = 5.09, P = 0.01 2, 21
Endothelium-independent (SNP%) 247 ± 126 284 ± 147 261 ± 152 F = 1.18, P = 0.32 2, 21
Macrovascular function
Endothelium-dependent (FMD%) 9.4 ± 6.8 12.0 ± 10.0 12.0 ± 8.1 F = 1.60, P = 0.21 2, 19
Endothelium-independent (GTN%) 22 ± 7.4 23 ± 7.2 24 ± 7.2 F = 0.31, P = 0.74 2, 19
Results are expressed as mean ± standard deviation. aDifferent from baseline. bDifferent from 2 weeks. Ach, acetylcholine; FMD, flow-mediated dilatation; GTN,
glyceryl trinitrate-mediated dilatation; SNP, sodium nitroprusside.
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were not associated with microvascular or macrovascu-
lar endothelial function in RA. Similarly, changes in
inflammatory markers did not consistently relate to
change in vascular function after anti-TNF-a treatment,
despite a transient improvement in microvascular
endothelial function. Global CVD risk, assessed by using
several different algorithms, inversely correlated with
microvascular endothelium-dependent function and
macrovascular endothelium-independent function in the
cross-sectional study, and some classical CVD risk fac-
tors improved after anti-TNF-a treatment.
RA is characterized by increased systemic inflammation,
which has been hypothesized to affect the vasculature and
contribute to accelerated atherosclerosis [30]. However,
the present findings suggest that systemic markers of
inflammation (ESR, CRP, and DAS28) do not relate to
endothelial function in two separate vascular beds, in a
cross-sectional or longitudinal study. It is worth noting
that a trend was seen for an association between microvas-
cular endothelium-dependent function and CRP in the
cross-sectional study; however, given the number of asso-
ciations that were examined, this could be a chance find-
ing. In the longitudinal study, ΔCRP was associated with
change in macrovascular endothelium-dependent function
at 2 weeks, but because macrovascular endothelial func-
tion did not significantly improve with anti-TNF-a treat-
ment, it is difficult to interpret the implication of this
association. In the microvasculature, conflicting associa-
tions between endothelial function and disease-related
markers of inflammation are reported: one study found an
association with TNF-a but not with ESR or CRP [31]; in
another, endothelial function was associated with CRP
only [10]; and yet another study reported no associations
at all [11]. Similarly, a number of studies in the macrovas-
culature reported no associations between disease-related
markers of inflammation and macrovascular endothelium-
dependent function [32,33]. Studies that have reported
associations present an inconsistent picture, with some
finding an association with CRP but not ESR [34], or with
DAS28 only [35]. Likewise, the majority of longitudinal
studies found no correlations between change in disease-
related markers of inflammation and change in microvas-
cular and macrovascular endothelial function in response
to antiinflammatory treatment, with only one report of an
association for macrovascular endothelium-dependent
function [9]. Collectively, these findings suggest that the
relation between endothelial function and disease-related
markers of inflammation may not be as strong as pre-
viously suggested.
The transient improvement in microvascular endothe-
lium-dependent function after treatment with anti-TNF-
a resonates with the findings of a previous study. Komai
and colleagues [36] found improvements in microvascu-
lar endothelium-dependent function after 2 weeks of
treatment with anti-TNF-a when assessing microvascular
endothelium-dependent function. In addition, although
lower than that at 2 weeks, endothelial function was still
increased after 6 weeks of treatment [36]. Therefore, it is
possible that after an initial improvement, a gradual
decrease in microvascular endothelial function occurs
between 6 weeks and 12 weeks. Without a 6-week assess-
ment in the current study, this must remain speculation.
In contrast, Hansel and colleagues [37] observed no
change in microvascular endothelium-dependent func-
tion at 2 weeks in RA patients; however, these patients
exhibited consistently lower disease-related inflammation
than did the present cohort. Given that elevated baseline
inflammation was associated with greater change in
endothelial function, it is possible that change in
endothelial function after treatment is unlikely in patients
with low disease-related inflammation, and this may
explain the seemingly contrasting findings. In line with
our findings, in patients with high baseline disease-
related inflammation, short-term improvement in micro-
vascular endothelial function after anti-inflammatory
treatment has been reported [38]. Although no long-term
follow-up period was applied, the findings support the
notion that, in patients with elevated inflammatory mar-
kers, acute improvement in microvascular endothelial
function is more likely than longer-term improvements
after treatment with anti-TNF-a.
Macrovascular endothelium-dependent function did
not change in response to 3 months of anti-TNF-a treat-
ment, which is in contrast to previous studies [39-41].
Comparison of the patients included in these studies
revealed that average baseline macrovascular endothe-
lium-dependent function was better in the current study
than in previous RA patient samples (9.4% versus 2.8% to
7.0%, respectively). Studies that included a healthy con-
trol group showed lower baseline macrovascular
endothelium-dependent function in the RA patients
[39,42]. However, in the present study, the baseline
macrovascular endothelium-dependent function of the
RA patients was similar to that of healthy control partici-
pants (data not shown), therefore making an improve-
ment in response to anti-TNF-a unlikely. Thus, it is
possible that treatment with anti-TNF-a may have less
impact in RA patients who have similar endothelial func-
tion than in healthy individuals.
The majority of individual classical CVD risk factors
did not associate with endothelium-dependent function
in RA in the cross-sectional study, with age being an
exception. In the general population, the association
between classical CVD risk factors and endothelial func-
tion has been well characterized [43]. To our knowledge,
no study of RA patients has examined the impact of clas-
sical CVD risk factors on microvascular endothelial func-
tion, and only a few studies have examined the effects of
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classical CVD risk factors on macrovascular endothelial
function [32,34,44]. Associations between endothelium-
dependent function and lipid levels were present in some
[34,44], but not all [32] studies. In the longitudinal study,
classical CVD risk factors (SBP, DBP, and HDL choles-
terol) improved after reducing RA disease-related inflam-
mation, which is in agreement with other studies [45].
This suggests that inflammation might contribute to the
development of classical CVD risk factors in patients
with RA. Despite the improvement in classical CVD risk
factors with anti-TNF-a therapy, it should be noted that
no direct associations were found between the improve-
ment in disease activity and risk factors.
The observation that microvascular but not macrovascu-
lar endothelium-dependent function most commonly
associated with global CVD risk algorithms and that only
microvascular endothelium-dependent function changed
after treatment with anti-TNF-a highlights the importance
of examining endothelial function in more than one vascu-
lar bed. Microvessels make up a much larger proportion of
the vasculature than do macrovessels, and may therefore
have greater exposure to injurious stimuli [46]. Conse-
quently, it is possible that even small changes in global
CVD risk could have a greater effect on microvascular
endothelium-dependent function. Therefore, assessments
that examine both vascular beds may provide more mean-
ingful clinical information on vascular risk in RA. Even
though ED has been associated with clinical end points in
patients with cardiovascular disease [4], only one such
study with a small sample has reported that high levels of
carotid artery intima-media thickness (a subclinical mea-
sure of atherosclerosis) are predictive of hard cardiac end
points in RA [47]. Therefore, further research is necessary
to explore which vascular assessment is the best predictor
of cardiac end points in RA patients.
In the macrocirculation, endothelium-independent func-
tion was associated with the FRS, Reynolds Risk Score,
QRISK 2, insulin resistance, SBP, presence of high choles-
terol levels, and hypertension. Evidence indicates that, in
healthy individuals with CVD risk factors, abnormalities in
endothelium-independent function may occur in the
absence of abnormalities in endothelium-dependent func-
tion [48]. Further, macrovascular endothelium-indepen-
dent function, but not macrovascular endothelium-
dependent function, was related to a reduction in SBP
after 12 and 24 weeks of treatment in patients with hyper-
tension [49]. These findings indicate that CVD risk factors
may differentially affect endothelial and smooth muscle
cell function, particularly in the macrovasculature. In the
current study, endothelium-independent function was sig-
nificantly lower in patients with hypertension, and some
evidence suggests that CVD risk factors like hypertension
degrade cyclic guanosine monophosphate (cGMP) [50], a
second messenger responsible for the relaxation of
vascular smooth muscle cells. In addition, in vitro studies
have shown that soluble guanylyl cyclase, an enzyme
responsible for activating cGMP, has reduced sensitivity to
NO in hypertensive rats [51]. This means that, even if ade-
quate NO is released from the endothelial cells, abnormal-
ities in smooth muscle cell signalling could still lead to a
reduced vasodilatory response. Thus, examination of vas-
cular function should include combined assessments of
endothelial function and smooth muscle cell function.
The strength of the present work was the inclusion of a
large cohort of RA patients at baseline, and the longitudi-
nal assessment of patients newly starting anti-TNF-a
treatment. Such a study design allowed the investigation
of specific predictors of endothelial function at baseline
and over a protracted timescale. Another strength of the
study was the extensive characterization of CVD risk by
using multiple global CVD risk scores (FRS, TCSCORE,
TC:HDL SCORE, Reynolds risk score, and QRISK2), along
with comprehensive assessment of CVD risk factors,
including HOMA and QUICKI. Unfortunately, the longi-
tudinal study did not have a no-treatment RA control
group, for obvious ethical reasons. It is acknowledged that
the inclusion of a patient group taking stable medication
could have strengthened the design of the study, as it
would have allowed exploration of potential fluctuations
in endothelial function. However, such a control group is
likely to have lower baseline levels of disease-related
inflammation, making comparisons to patients with active
inflammation difficult. Additional limitations include the
inability to examine the effects of other disease-modifying
antirheumatic drugs, as well as treatment with corticoster-
oids. Further research is necessary to establish whether
alternative anti-inflammatory medications may exert dif-
ferent effects on endothelial function. Furthermore, the
use of other biomarkers of inflammation (for example,
CD40, interleukin 6) may help to unravel important path-
ways that may contribute to vascular pathology in RA.
Finally, the etiology of RA has a considerable genetic com-
ponent in particular; certain human leukocyte antigen
alleles appear to associate with worse macrovascular
endothelium-dependent function in this group of patients
[52]. More recent studies have reported that deletion of
certain protective genes (such as CCR5Δ32) can result in
lower macrovascular endothelium-dependent function in
RA [53]. Thus, further work examining the genetic influ-
ence on endothelial function is required.
Conclusion
In summary, the present findings suggest that global
CVD risk algorithms may be better predictors of vascu-
lar health than individual CVD risk factors and systemic
markers of disease-related inflammation in patients with
RA. Furthermore, classical CVD risk and anti-TNF-a
treatment appear to differentially impact microvascular
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and macrovascular endothelial function; therefore,
assessments of endothelial function should be performed
in both vascular beds. Further studies are needed to
confirm whether assessments of vascular function are
predictive of long-term CV outcomes in RA.
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